Prolysis Ltd.
This article was originally published in Start Up
Executive Summary
Prolysis Ltd. reckons it has a head start over other biotechs seeking novel anti-infectives because its core technology--a series of whole cell assays targeting critical bacterial pathways--allows it to select, early on, only those compounds that get inside the bacterial cell.